plus cisplatin and paclitaxel, followed by adjuvant cisplatin and gemcitabine; the 5-year OS rate was 56%. 59 In RTOG 0233, 97 patients received twice-daily radiation with concurrent paclitaxel plus cisplatin or 5-FU plus cisplatin; the 5-year OS was
Search Results
Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Peter E. Clark, Tracy M. Downs, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer, and Lisa A. Gurski
Jonas A. de Souza, Mark J. Ratain, and A. Mark Fendrick
Novotny W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J Med 2004 ; 350 : 2335 - 2342 . 17 Sandler A Gray R Perry MC . Paclitaxel-carboplatin alone or with bevacizumab for non
Benjamin E. Greer, Wui-Jin Koh, Nadeem Abu-Rustum, Michael A. Bookman, Robert E. Bristow, Susana M. Campos, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Patricia J. Eifel, Warner K. Huh, Wainwright Jaggernauth, Daniel S. Kapp, John J. Kavanagh, John R. Lurain III, Mark Morgan, Robert J. Morgan Jr, C. Bethan Powell, Steven W. Remmenga, R. Kevin Reynolds, Angeles Alvarez Secord, William Small Jr, and Nelson Teng
endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study [abstract] . 39th Annual Meeting of the Society of Gynecologic Oncologists ; Tampa, FL
David S. Ettinger, Gregory J. Riely, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Ramaswamy Govindan, Frederic W. Grannis Jr, Stefan C. Grant, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Rudy P. Lackner, Inga T. Lennes, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Mary C. Pinder-Schenck, Katherine M. Pisters, Karen Reckamp, Eric Rohren, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Douglas E. Wood, Stephen C. Yang, Kristina Gregory, and Miranda Hughes
for thymoma. 20 , 88 , 89 However, nonanthracycline regimens (eg, cisplatin/etoposide [with or without ifosfamide], carboplatin/paclitaxel) may be useful for patients who cannot tolerate the more aggressive regimens. 89 , 90 For thymic carcinoma, the
David S. Ettinger, Dara L. Aisner, Douglas E. Wood, Wallace Akerley, Jessica Bauman, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D'Amico, Thomas J. Dilling, Michael Dobelbower, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Sandip P. Patel, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes
update, the NCCN panel added a recommendation for atezolizumab/carboplatin/paclitaxel/bevacizumab (category 1) as first-line therapy for patients with metastatic nonsquamous NSCLC based on results of a recent phase III randomized trial (IMpower150). 78
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, and Richard Zellars
addition of neoadjuvant trastuzumab to paclitaxel followed by FEC chemotherapy (fluorouracil, epirubicin, and cyclophosphamide) was associated with an increase in the pathologic complete response rate from 26% to 65.2% ( P = .016). 107 Thus, the
Sumanta K. Pal, Matthew I. Milowsky, and Elizabeth R. Plimack
-positive disease to a regimen of paclitaxel, gemcitabine, and cisplatin (PGC) or observation. 25 The study ultimately showed a survival advantage with adjuvant PGC compared with observation (median not reached [NR] vs 26 months; P <.0009). Unfortunately, the
Laura M. Spring, Yael Bar, and Steven J. Isakoff
(or preceded by) the THP regimen, with docetaxel often substituted by weekly paclitaxel for improved tolerability. The role of anthracyclines in the neoadjuvant treatment of HER2+ breast cancer has been a topic of discussion, given the increasing
Tiffany Li, Hannah C. Timmins, Terry Trinh, David Mizrahi, Michelle Harrison, Lisa G. Horvath, Peter Grimison, Michael Friedlander, Matthew C. Kiernan, Madeleine T. King, Claudia Rutherford, David Goldstein, and Susanna B. Park
-EONS-EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up . Ann Oncol 2020 ; 31 : 1306 – 1319 . 32739407 6. Park SB , Kwok JB , Asher R , Clinical and genetic predictors of paclitaxel neurotoxicity based on
Holly Dushkin and Massimo Cristofanilli
with FAC followed by paclitaxel. The pathologic complete response rate was significantly higher in those treated with FAC and paclitaxel (25% vs. 10%). The addition of paclitaxel led to improvement in progression-free (27 vs. 18 months) and median
